Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC Sept 2021 | Ongoing studies for datopotamab deruxtecan in NSCLC

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses updates from the non-small cell lung cancer (NSCLC) cohort of TROPION-PanTumor01, a Phase I study evaluating datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (NCT03401385). Dato-DXd showed efficacy in patients with and without driver mutations and it is currently being assessed in a Phase II study in patients with NSCLC with actionable genomic alterations (TROPION-Lung05, NCT04484142), as well as in a Phase III study comparing Dato-DXd versus docetaxel in previously treated advanced or metastatic NSCLC without actionable genomic alterations (TROPION-Lung01, NCT04656652). Although preliminary data is highly promising, further results are eagerly awaited. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.